A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec; Liraglutide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DUAL I China
- Sponsors Novo Nordisk
- 10 Jan 2019 Planned primary completion date changed from 10 Dec 2018 to 21 Jun 2019.
- 10 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated